PeraHealth CEO and leadership

Michael Rothman co-founded PeraHealth in 2005 with his brother Steven, following the avoidable death of their mother, Florence.

His career began at IBM’s General Technology Division, after he earned his PhD in quantum chemistry. At IBM, he worked in optimization, mathematical modeling, and data analysis; work that led to a doubling of memory chip yields for mainframes. Michael also spent time at IBM’s T. J. Watson Research Labs, in the AI department, engaged in research in machine learning.

Michael is a natural interpreter of information. As a manager and executive consultant for the IBM Consulting group, his duties included translating mathematical results into effective business strategies for major banks and financial institutions. Later, as Senior Vice President for Strategic Information at First USA Bank, Michael established a database to better determine customer preferences.

In 2000, he founded Michael Rothman & Associates to focus on data analysis and product development through consulting, patent filing, and joint ventures. Projects have included developing a system generating customized discharge forms for hospitals, helping determine cash flow and profitability for a pharmaceutical company’s newly introduced drugs, and pro bono work analyzing mortality data for a guide dog school.

Michael earned an ScB and ScM in Chemistry from Brown University, and went on to earn a PhD in Chemistry from the University of Michigan.

With more than 25 years in technology and healthcare, Brad has proven that thoughtful leadership is key to building world class products. Products that deliver real value and make measurable improvements in patients’ lives. Brad has held leadership positions in multiple healthcare companies, such as Premier, Inc. and Allscripts, as well as FDA regulated medical device companies, including Johnson & Johnson and Monarch Medical Technologies. Recent focus has been on technologies in the data science space, utilizing machine learning, predictive analytics, and big data techniques to build products that deliver in ways unimaginable just a few years ago. Brad has degrees from Virginia Commonwealth and Duke Universities.

James Hayne is a Shareholder at Dodson, Shelton & Nelson, P.A.; Chief Financial Officer at PeraHealth The Rothman Index; and CFO at PERAHEALTH INC and is based in Charlotte, North Carolina. He has worked as Shareholder - Technology and Life Sciences Practice Group Leader at Elliott Davis, Shareholder at Hayne CPA PLLC, and Principal at Lunsford & Strickland PA. James attended NC State University between 1984 and 1988.

Carolyn Scott is a Chief Customer Officer at PERAHEALTH INC.

Michael Rothman co-founded PeraHealth in 2005 with his brother Steven, following the avoidable death of their mother, Florence.

His career began at IBM’s General Technology Division, after he earned his PhD in quantum chemistry. At IBM, he worked in optimization, mathematical modeling, and data analysis; work that led to a doubling of memory chip yields for mainframes. Michael also spent time at IBM’s T. J. Watson Research Labs, in the AI department, engaged in research in machine learning.

Michael is a natural interpreter of information. As a manager and executive consultant for the IBM Consulting group, his duties included translating mathematical results into effective business strategies for major banks and financial institutions. Later, as Senior Vice President for Strategic Information at First USA Bank, Michael established a database to better determine customer preferences.

In 2000, he founded Michael Rothman & Associates to focus on data analysis and product development through consulting, patent filing, and joint ventures. Projects have included developing a system generating customized discharge forms for hospitals, helping determine cash flow and profitability for a pharmaceutical company’s newly introduced drugs, and pro bono work analyzing mortality data for a guide dog school.

Michael earned an ScB and ScM in Chemistry from Brown University, and went on to earn a PhD in Chemistry from the University of Michigan.